A Potential Therapeutic Application of SET/I2PP2A Inhibitor OP449 for Canine T-cell Lymphoma

Access this Article

Search this Article

Author(s)

    • FUJIWARA Nobuyuki
    • Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan
    • KAWASAKI Hideyoshi
    • Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan
    • YABE Ryotaro
    • Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan
    • CHRISTENSEN Dale J.
    • Department of Medicine (Hematology), Duke University, Durham, NC, U.S.A.|Oncotide Pharmaceuticals, Inc., Research Triangle Park, NC, U.S.A.
    • VITEK Michael P.
    • Departments of Medicine (Neurology) and Neurobiology, Duke University, Durham, NC, U.S.A.
    • MIZUNO Takuya
    • Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan
    • SATO Koichi
    • Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan
    • OHAMA Takashi
    • Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan

Abstract

Lymphoma is one of the most common malignant tumors in canine. Chemotherapy results in a high rate of remission; however, relapse and clinical drug resistance are usually seen within a year. Protein phosphatase 2A (PP2A) acts as a tumor suppressor and plays a critical role in mammalian cell transformation. Increased protein levels of SET, endogenous PP2A inhibitor, have been reported to correlate with poor prognosis in human leukemia. Here, we test the potential therapeutic role for a SET antagonist in canine lymphoma. We observed SET protein levels increased in multiple canine lymphoma cell lines compared with primary peripheral blood cells. A novel SET antagonist OP449 increased PP2A activity and effectively killed SET high-expressing canine lymphoma cells, but not SET low-expressing cells. Caspase-3 activation and enhanced Annexin V positive staining were observed after OP449 treatment, suggesting apoptotic cell death by OP449. Consistent with this, pan-caspase inhibitor Z-VAD-FMK blocked OP449 induced cell death. These data demonstrated the potential therapeutic application of SET antagonists for canine lymphoma.

Journal

  • Journal of Veterinary Medical Science

    Journal of Veterinary Medical Science 75(3), 349-354, 2013

    JAPANESE SOCIETY OF VETERINARY SCIENCE

Codes

  • NII Article ID (NAID)
    130001879628
  • NII NACSIS-CAT ID (NCID)
    AA10796138
  • Text Lang
    ENG
  • Article Type
    journal article
  • ISSN
    0916-7250
  • Data Source
    IR  J-STAGE 
Page Top